Baker Bros. Advisors LP’s BeOne Medicines holding rose to 7.8%, representing 115457154.00 shares, after Options were exercised for 30,768 ADS. The position is classified as activist under a 13D, while the stated purpose says there are no plans for extraordinary corporate transactions involving BeOne Medicines.
Key Highlights
- The options were exercised at $36.83 per ADS, with total Acquisition spending of $1,133,185.44.
- Baker Brothers Life Sciences, L.P. accounts for 7.1% of the class, while 667, L.P. accounts for 0.6%.
- Michael Goller and Ranjeev Krishana have no voting or dispositive power over the exercised options or resulting ADS.
BeOne Medicines Ltd. (NASDAQ: ONC) is now 7.8% owned by Baker Bros. Advisors LP, whose position rose to 115,457,154 shares. The stake is classified as activist under a 13D. The stated purpose was the exercise of options to purchase ADS, while the investors said they had no plans or proposals involving an extraordinary corporate transaction. The position is associated with Baker Bros. Advisors (GP) LLC and Julian C. Baker, each also reporting 7.8%. Felix J. Baker reports 7.8%, while FBB3 LLC reports 0.01%.
Baker Funds’ Ownership Breakdown
Baker Brothers Life Sciences, L.P. reports 104,889,368 ordinary shares that it owns or has the right to acquire within 60 days, equal to 7.1% of the class. 667, L.P. reports 9,498,367 ordinary shares on the same basis, equal to 0.6%. The two funds together report 114,387,735 ordinary shares and 7.7% of the class outstanding. The securities are ordinary shares with a Par Value of $0.0001 per share, and each ADS represents thirteen ordinary shares. The reported holdings also include interests connected with Michael Goller and Ranjeev Krishana, who previously served on BeOne Medicines’ board as representatives of the funds.
ADS Options Exercised
The transaction resulted from the exercise of 15,384 options held directly by each of Goller and Krishana, at $36.83 per ADS. The amounts spent were $566,592.72 for the options held by each individual, or $1,133,185.44 in total. The adviser funded the exercises through loans from 667 and Life Sciences. Under those agreements, the adviser controls the timing of exercise and has dispositive power over the exercised options and the resulting ADS. Goller and Krishana have no voting or dispositive power over the exercised options or ADS and no direct pecuniary interest in them.
Stated Plans Remain Limited
The stated purpose covers the option exercise and says there are no plans or proposals concerning an extraordinary corporate transaction involving BeOne Medicines. The listed examples include matters addressed in the relevant provisions of the activist 13D disclosure. The proceeds agreements also set out how the adviser directs future sales of the ADS received through the exercise. Goller and Krishana previously served on the board, and their compensation arrangements are tied to the funds’ entitlement to the economic interest in options and other compensation connected with their service. FBB3 LLC reports 144,517 ordinary shares, representing 0.01% of the class. The reported interests therefore include the adviser, its general partner, the Baker individuals and the affiliated entity, alongside the funds’ reported holdings.



Please wait processing your request...